Abstract 12866: Prognostic Impact of LR11, a Novel Proliferative Marker of Vascular Smooth Muscle Cells, on Long-term Clinical Outcomes in Patients wwith Coronary Artery Disease
Purpose: LR11, a member of LDL receptor family, is a novel proliferation marker of intimal smooth muscle cells (SMCs). LR11 is secreted in soluble form (sLR11) by proteolytic shedding and has biological activity toward SMC migration. We previously demonstrated that circulating sLR11 is positively correlated wit carotid intima-medial thickeness (IMT) independent of classical atherosclerotic risk factors and significantly associated with severity of coronary arery disease (CAD). However, the association between sLR11 and long-term clinical outcomes remain uncertain. We therefore evaluated the prognostic value of circulating sLR11 in patients with coronary artery disease (CAD).
Methods: Consecutive 439 patients (mean age 66.5±8.8 years, male 80.4%) treated with coronary intervention from 2003 to 2004 in our institution was enrolled in the present study. We divided the patients into quartiles according to preprocedual sLR11. The primary endpoint was the major adverse cardiac and cerebrovascular events (MACCE) including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.
Results: The incidence of MACCE during median follow-up of 2876 days was significantly different among quartiles (14.8 % vs. 19.1 % vs. 24.5% vs. 31.2 %, log-rank p = 0.002). On multivariate Cox hazard regression model, sLR11 was independent predictor of MACCE (HR 1.25, 95%CI 1.02-1.55, P = 0.034).
Conclusion: Our results demonstrated that elevated sLR11 could predict higher long-term adverse cardiac events in patients with CAD.
- © 2013 by American Heart Association, Inc.